Formulation and Stability Study of Omeprazole Oral Liquid Suspension for Pediatric Patients

被引:11
|
作者
Boscolo, Oriana [1 ]
Perra, Francesco [1 ,2 ]
Salvo, Leandro [1 ]
Buontempo, Fabian [1 ,3 ]
Lucangioli, Silvia [1 ,4 ]
机构
[1] Univ Buenos Aires, Buenos Aires, DF, Argentina
[2] Univ Cagliari, Cagliari, Italy
[3] Hosp Pediat JP Garrahan, Buenos Aires, DF, Argentina
[4] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina
关键词
omeprazole; formulation; stability study; pediatric; acid-related diseases; PROTON PUMP INHIBITORS;
D O I
10.1177/0018578719844704
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives:To develop and to study the physicochemical and microbiological stability of omeprazole liquid oral formulations used as therapeutic agent in many acid-related disorders, for pediatric use. Furthermore, to optimize and validate a stability-indicating high-performance liquid chromatography (HPLC) method for the analysis of omeprazole in the studied formulations.Method:Oral liquid suspensions of omeprazole were prepared at 2 mg/mL using crushed omeprazole pellets (formulation A) and pure omeprazole (formulation B) with a complete vehicle including humectant, suspending, sweetening, antioxidant, and flavoring agents. Samples were stored at 4 degrees C and 25 degrees C. Omeprazole content of each formulation was analyzed in triplicate using micro-HPLC at 0, 3, 7, 14, 30, 60, 90, 120, and 150 days. Other parameters were also determined, such as appearance, pH, resuspendibility, and viscosity. Microbiological studies were conducted according to the United Stated Pharmacopeia (USP) guidelines for non-sterile products.Results:Formulation A stayed physicochemical and microbiologically stable at refrigerated (4 degrees C) conditions during at least 150 days and it only stayed stable during 14 days at 25 degrees C. Formulation B was stayed physicochemical and microbiologically stable at refrigerated (4 degrees C) conditions at least 90 days, but it is not recommended to store at 25 degrees C for more than 1 day.Conclusions:Formulation A and formulation B can be stored for at least 150 and 90 days, respectively, at refrigerated conditions. Formulation A can be stored at room temperature for 14 days. Both formulations are perfectly suitable for pediatric patients who are usually notable to swallow solid oral formulations. The proposed analytical method was suitable for the study of stability of different formulations.
引用
收藏
页码:314 / 322
页数:9
相关论文
共 50 条
  • [41] Stability Study of Baclofen in an Oral Powder Form Compounded for Pediatric Patients in Japan
    Saito, Jumpei
    Hanawa, Takehisa
    Ozawa, Ayuna
    Matsumoto, Takahiro
    Yoshikawa, Nozomi
    Harada, Tsutomu
    Iwahashi, Kana
    Yamatani, Akimasa
    CHILDREN-BASEL, 2022, 9 (09):
  • [42] Stability study of a clonidine oral solution in a novel vehicle designed for pediatric patients
    Potier, Arnaud
    Voyat, Julien
    Nicolas, Alain
    PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2018, 23 (10) : 1067 - 1076
  • [43] Pediatric-friendly suspension for oral administration of pyrimethamine in congenital toxoplasmosis: Development and in use-stability study
    Neis, Julya Sarmento
    Zamberlan, Amanda Maccangnan
    Saraiva, Emanuele Saul
    Pommer, Eduardo Costa
    Dias, Micheline Silva
    Ferreira, Luana Mota
    Adams, Andrea Ines Horn
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2024, 102
  • [44] Correction to: First Development, Optimization, and Stability Control of a Pediatric Oral Atenolol Formulation
    Mauro Morri
    Patricia Castellano
    Darío Leonardi
    Silvana Vignaduzzo
    AAPS PharmSciTech, 2018, 19 : 3907 - 3907
  • [45] Bioequivalence of a New Pediatric Paracetamol Oral Suspension Compared With a Marketed Formulation in Healthy Adults: A Randomized, Open-Label Study
    Grim, Jiri
    Armogida, Marianna
    Kachroo, Preeti
    Siddiqui, Kamran
    Cavinato, Mauro
    Araga, Mako
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2024, 100
  • [46] Expanded Colesevelam Administration Options With Oral Suspension Formulation for Patients With Diabetes and Hypercholesterolemia
    Dayer-Berenson, Linda
    Finckenor, Mary
    POSTGRADUATE MEDICINE, 2014, 126 (03) : 126 - 134
  • [47] Analytical Method and Stability Study for Oral Suspension of Idebenone in Syrspend
    Porru, Emanuele
    Piro, Filomena
    Comito, Rossana
    Mosendz, Anastasiia
    Minniti, Elirosa
    Conti, Matteo
    Stancari, Alessandra
    Violante, Francesco Saverio
    SEPARATIONS, 2023, 10 (09)
  • [48] Population pharmacokinetic analysis of oral lansoprazole suspension in pediatric patients.
    Palaparthy, R
    DiGiacinto, J
    Kastrissios, H
    Scheibel, W
    Graumlich, JF
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P57 - P57
  • [49] Efficacy and Safety of Oral Budesonide Suspension in Pediatric Patients With Eosinophilic Esophagitis
    Gupta, Sandeep K.
    Vitanza, Joanne M.
    Collins, Margaret H.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (01) : 66 - U135
  • [50] Therapeutic use of an extemporaneously prepared oral suspension of tacrolimus in pediatric patients
    McGhee, B
    McCombs, JR
    Boyle, G
    Webber, SA
    Reyes, JR
    TRANSPLANTATION, 1997, 64 (06) : 941 - 942